Bookmark and Share

BSD Medical’s (BSDM) China Distributor Orders Two BSD-2000 Hyperthermia Systems

Sep. 9, 2010 (Business Wire) — BSD Medical Corporation (NASDAQ: BSDM) (the “Company” or “BSD”) announced today that Dalian Orientech Co. Ltd (“Orientech”), the Company’s exclusive China distributor, has ordered two BSD-2000 Hyperthermia Systems (BSD-2000). The BSD-2000 System utilizes BSD’s proprietary synchronous phased array technology to non-invasively target therapeutic heating (hyperthermia) to certain cancerous tumors, including those located deep within the body. Clinical studies have shown that hyperthermia treatment can kill cancer cells directly as well as increase the effectiveness of other cancer therapies, including radiation therapy, for the treatment of certain tumors.

Hyperthermia cancer therapy has a strong following in China, and Orientech controls about 65% of the market. The Orientech sales force covers 23 provinces. After shipping the two systems, the Company will have sold 19 BSD-2000 Hyperthermia Systems to Orientech.

Hyperthermia has been used in China for the treatment of cancer for many years. The hyperthermia market in China has historically been supported by Chinese manufactured systems. The market objective for BSD in China is to continue to expand and upgrade the existing market for clinical hyperthermia equipment to the advanced features of the BSD-2000.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. The BSD-2000 is restricted to investigational use in the US. For further information visit BSD Medical’s website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Thursday, September 9th, 2010 Uncategorized
Top Small Cap Market News